Dietary Vitamin D and Its Metabolites Non-Genomically Stabilize the Endothelium

Vitamin D is a known modulator of inflammation. Native dietary vitamin D3 is thought to be bio-inactive, and beneficial vitamin D3 effects are thought to be largely mediated by the metabolite 1,25(OH)2D3. Reduced serum levels of the most commonly measured precursor metabolite, 25(OH)D3, is linked to an increased risk of multiple inflammatory diseases, including: cardiovascular disease, arthritis, multiple sclerosis, and sepsis. Common to all of these diseases is the disruption of endothelial stability and an enhancement of vascular leak. We previously performed an unbiased chemical suppressor screen on a genetic model of vascular instability, and identified cholecalciferol (D3, dietary Vitamin D3) as a factor that had profound and immediate stabilizing and therapeutic effects in that model. In this manuscript we show that the presumed inactive sterol, D3, is actually a potent and general mediator of endothelial stability at physiologically relevant concentrations. We further demonstrate that this phenomenon is apparent in vitamin D3 metabolites 25(OH)D3 and 1,25(OH)2D3, and that the effects are independent of the canonical transcription-mediated vitamin D pathway. Our data suggests the presence of an alternative signaling modality by which D3 acts directly on endothelial cells to prevent vascular leak. The finding that D3 and its metabolites modulate endothelial stability may help explain the clinical correlations between low serum vitamin D levels and the many human diseases with well-described vascular dysfunction phenotypes.

[1]  H. Hemilä,et al.  Vitamin D supplementation and upper respiratory tract infections in adolescent swimmers: a randomized controlled trial. , 2015, Pediatric exercise science.

[2]  Weiquan Zhu,et al.  Strategy for Identifying Repurposed Drugs for the Treatment of Cerebral Cavernous Malformation , 2015, Circulation.

[3]  K. Ng Vitamin D for Prevention and Treatment of Colorectal Cancer: What is the Evidence? , 2014, Current Colorectal Cancer Reports.

[4]  D. Agrawal,et al.  Vitamin D and inflammatory diseases , 2014, Journal of inflammation research.

[5]  Dean Y. Li,et al.  ARF6 Inhibition Stabilizes the Vasculature and Enhances Survival during Endotoxic Shock , 2014, The Journal of Immunology.

[6]  E. Giovannucci,et al.  Association of Low Serum 25-Hydroxyvitamin D Levels and Sepsis in the Critically Ill , 2014, Critical care medicine.

[7]  Dean Y. Li,et al.  Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability , 2012, Nature.

[8]  Dean Y. Li,et al.  Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels. , 2012, Cancer cell.

[9]  J.,et al.  The New England Journal of Medicine , 2012 .

[10]  M. Haussler,et al.  Vitamin D receptor (VDR)-mediated actions of 1α,25(OH)₂vitamin D₃: genomic and non-genomic mechanisms. , 2011, Best practice & research. Clinical endocrinology & metabolism.

[11]  Lei Xu,et al.  Normalization of the vasculature for treatment of cancer and other diseases. , 2011, Physiological reviews.

[12]  Hugh Rosen,et al.  Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus , 2011, Proceedings of the National Academy of Sciences.

[13]  R. A. Boer Vitamin D and cardiovascular disease: a jack of all trades? , 2011 .

[14]  R. D. de Boer Vitamin D and cardiovascular disease: a jack of all trades? , 2011, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[15]  T. Spector,et al.  Inherited Variation in Vitamin D Genes Is Associated With Predisposition to Autoimmune Disease Type 1 Diabetes , 2011, Diabetes.

[16]  E. Giovannucci,et al.  Association of low serum 25-hydroxyvitamin D levels and mortality in the critically ill* , 2011, Critical care medicine.

[17]  A. Reimold,et al.  Prevalence of Vitamin D Insufficiency/Deficiency in Rheumatoid Arthritis and Associations with Disease Severity and Activity , 2011, The Journal of Rheumatology.

[18]  B. Clarke,et al.  Vitamin D insufficiency. , 2011, Mayo Clinic proceedings.

[19]  B. Horne,et al.  Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. , 2010, The American journal of cardiology.

[20]  A. Ascherio,et al.  Vitamin D and multiple sclerosis , 2010, The Lancet Neurology.

[21]  Y. Shoenfeld,et al.  Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? , 2010, Annals of the rheumatic diseases.

[22]  J. Pike,et al.  A Downstream Intergenic Cluster of Regulatory Enhancers Contributes to the Induction of CYP24A1 Expression by 1α,25-Dihydroxyvitamin D3* , 2010, The Journal of Biological Chemistry.

[23]  Dean Y. Li,et al.  Targeting Robo4-Dependent Slit Signaling to Survive the Cytokine Storm in Sepsis and Influenza , 2010, Science Translational Medicine.

[24]  A. Kalueff,et al.  25-Hydroxyvitamin D3 is an agonistic vitamin D receptor ligand , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  K. Jang,et al.  COMP-angiopoietin-1 decreases lipopolysaccharide-induced acute kidney injury. , 2009, Kidney international.

[26]  M. Decramer,et al.  Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene , 2009, Thorax.

[27]  Christopher A. Jones,et al.  Slit2–Robo4 signalling promotes vascular stability by blocking Arf6 activity , 2009, Nature Cell Biology.

[28]  Elisabetta Dejana,et al.  The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. , 2009, Developmental cell.

[29]  L. Laffel,et al.  Significant vitamin D deficiency in youth with type 1 diabetes mellitus. , 2009, The Journal of pediatrics.

[30]  J. Mora,et al.  Vitamin effects on the immune system: vitamins A and D take centre stage , 2008, Nature Reviews Immunology.

[31]  B. Hollis,et al.  25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. , 2008, The American journal of clinical nutrition.

[32]  Michael J. Pencina,et al.  Vitamin D Deficiency and Risk of Cardiovascular Disease , 2008, Circulation.

[33]  E. Giovannucci Vitamin D status and cancer incidence and mortality. , 2008, Advances in experimental medicine and biology.

[34]  Jordan S. Pober,et al.  Evolving functions of endothelial cells in inflammation , 2007, Nature Reviews Immunology.

[35]  J. V. van Buul,et al.  ICAM-1-Mediated, Src- and Pyk2-Dependent Vascular Endothelial Cadherin Tyrosine Phosphorylation Is Required for Leukocyte Transendothelial Migration1 , 2007, The Journal of Immunology.

[36]  A. Norman,et al.  Minireview: vitamin D receptor: new assignments for an already busy receptor. , 2006, Endocrinology.

[37]  E. Warburton,et al.  Reduced Vitamin D in Acute Stroke , 2006, Stroke.

[38]  M. Broman,et al.  Cdc42 Regulates Adherens Junction Stability and Endothelial Permeability by Inducing α-Catenin Interaction With the Vascular Endothelial Cadherin Complex , 2005, Circulation research.

[39]  A. Malik,et al.  Signaling mechanisms regulating endothelial permeability. , 2006, Physiological reviews.

[40]  John H. White,et al.  Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. , 2005, Molecular endocrinology.

[41]  D. Cheresh,et al.  Tyrosine Phosphorylation of VE-cadherin Prevents Binding of p120- and β-Catenin and Maintains the Cellular Mesenchymal State* , 2005, Journal of Biological Chemistry.

[42]  R. Larkins,et al.  VITAMIN D METABOLISM , 1977, The Medical journal of Australia.

[43]  Jeffrey B. Cheng,et al.  Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. Campochiaro,et al.  Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood–retinal barrier , 2004, Gene Therapy.

[45]  B. Boyan,et al.  Membrane actions of vitamin D metabolites 1α,25(OH)2D3 and 24R,25(OH)2D3 are retained in growth plate cartilage cells from vitamin D receptor knockout mice , 2003, Journal of cellular biochemistry.

[46]  M. Holick,et al.  Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. , 2003, The American journal of clinical nutrition.

[47]  A. Ridley,et al.  Rho GTPases and the regulation of endothelial permeability. , 2002, Vascular pharmacology.

[48]  D. Wheeler,et al.  Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. , 2002, Journal of the American Society of Nephrology : JASN.

[49]  T. Chen,et al.  An evaluation of the biologic activity and vitamin D receptor binding affinity of the photoisomers of vitamin D3 and previtamin D3. , 2000, The Journal of nutritional biochemistry.

[50]  P. Schwartzberg,et al.  Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. , 1999, Molecular cell.

[51]  J. Loscalzo,et al.  Endothelial cells in physiology and in the pathophysiology of vascular disorders. , 1998, Blood.

[52]  A. C. Maiyar,et al.  1,25(OH)2-vitamin D3, a steroid hormone that produces biologic effects via both genomic and nongenomic pathways , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[53]  Joseph L. Napoli,et al.  Vitamin D Metabolism , 1984 .

[54]  T. Oppé,et al.  Vitamin D deficiency. , 1979, British medical journal.

[55]  J. Garland The New England Journal of Medicine. , 1961, Canadian Medical Association journal.

[56]  I. Macintyre Vitamin D metabolism. , 1973, The New England journal of medicine.

[57]  H. Nowicki,et al.  1,25-Dihydroxycholecalciferol: Identification of the Proposed Active Form of Vitamin D3 in the Intestine , 1971, Science.